Morgan Stanley analyst Michael Cyprys maintains Nasdaq (NASDAQ:NDAQ) with a Overweight and raises the price target from $68 to $71.
BioNexus Gene Lab Corp. Announces Pricing Of $5M Public Offering And Uplisting To The Nasdaq Capital Market
BioNexus Gene Lab Corp. ("BioNexus" or the "Company"), an emerging company in the business of selling chemical raw materials in the Southeast Asia region and the development of safe, effective, and
